Nihon Kohden Corporation (TYO:6849)
Japan · Delayed Price · Currency is JPY 1,622.50
+9.00 (0.56%)
At close: Dec 12, 2025
Nihon Kohden Revenue
Nihon Kohden had revenue of 58.10B JPY in the quarter ending September 30, 2025, with 2.73% growth. This brings the company's revenue in the last twelve months to 230.76B, up 4.31% year-over-year. In the fiscal year ending March 31, 2025, Nihon Kohden had annual revenue of 225.42B with 1.55% growth.
Revenue (ttm)
230.76B
Revenue Growth
+4.31%
P/S Ratio
1.15
Revenue / Employee
37.74M
Employees
6,114
Market Cap
264.64B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 225.42B | 3.44B | 1.55% |
| Mar 31, 2024 | 221.99B | 15.38B | 7.45% |
| Mar 31, 2023 | 206.60B | 1.47B | 0.72% |
| Mar 31, 2022 | 205.13B | 5.40B | 2.70% |
| Mar 31, 2021 | 199.73B | 14.72B | 7.96% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.42T |
| Otsuka Holdings | 2.42T |
| Astellas Pharma | 2.01T |
| Daiichi Sankyo Company | 1.98T |
| Chugai Pharmaceutical | 1.21T |
| Terumo | 1.06T |
| Olympus | 977.65B |
| HOYA Corporation | 892.50B |
Nihon Kohden News
- 8 days ago - Nihon Kohden Brings Advanced EEG Technology Built on 70 Years of Innovation to Booth #725 at the American Epilepsy Society 2025 Annual Meeting - Business Wire